These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Role of biological therapies in the development of personalized medicine. Jain KK Expert Opin Biol Ther; 2012 Jan; 12(1):1-5. PubMed ID: 22107592 [TBL] [Abstract][Full Text] [Related]
46. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Zhang R; Wang H; Agrawal S Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188 [TBL] [Abstract][Full Text] [Related]
47. Biological therapy of ovarian cancer: current directions. Bookman MA Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851 [TBL] [Abstract][Full Text] [Related]
51. Multi-specific antibodies for cancer immunotherapy. Jachimowicz RD; Borchmann S; Rothe A BioDrugs; 2014 Aug; 28(4):331-43. PubMed ID: 24638872 [TBL] [Abstract][Full Text] [Related]
52. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183 [TBL] [Abstract][Full Text] [Related]
53. MicroRNAs as targets for antisense-based therapeutics. Stenvang J; Kauppinen S Expert Opin Biol Ther; 2008 Jan; 8(1):59-81. PubMed ID: 18081537 [TBL] [Abstract][Full Text] [Related]
54. Antisense '97: a roundtable on the state of the industry. Nat Biotechnol; 1997 Jun; 15(6):519-24. PubMed ID: 9181572 [No Abstract] [Full Text] [Related]